Close
New

Medscape is available in 5 Language Editions – Choose your Edition here.

 

Type 2 Multiple Endocrine Neoplasia Treatment & Management

  • Author: Melanie L Richards, MD; Chief Editor: George T Griffing, MD  more...
 
Updated: Dec 11, 2015
 

Approach Considerations

Type 2A multiple endocrine neoplasia (MEN 2A) is treated with surgery. Preoperative medical treatment may consist of prostaglandin inhibitors to alleviate diarrhea that may be associated with medullary thyroid cancer.

Evaluation for pheochromocytomas is important because these should be removed before other surgical interventions. This evaluation can be performed before parathyroidectomy or thyroidectomy under a single general anesthetic if the patient is stable.

Pheochromocytoma

Preoperatively, prepare patients with pheochromocytomas by treating them with an alpha-blocker or a tyrosine hydroxylase inhibitor, such as metyrosine, for 1-2 weeks, after which administration of a beta-blocker can be considered. Reports of successful management using a calcium channel blocker rather than an alpha blocker have been noted. Many practitioners routinely treat patients with a beta-blocker, while others selectively treat patients based on blood pressure control and tachycardia.

Hypercalcemia

Patients presenting with severe hypercalcemia should first be hydrated, after which they should be treated with furosemide. If they remain severely hypercalcemic, consider treatment with calcitonin, glucocorticoids, or bisphosphonates (such as pamidronate). While bisphosphonates are most commonly used, cinacalcet, a calcimimetic, can also be effective at reducing serum calcium levels. These patients need urgent parathyroidectomy when calcium levels have been lowered, ideally below 14 mg/dL. Patients who are not surgical candidates may also benefit from cinacalcet.

Thyroid supplementation

Thyroid hormone supplementation is necessary following total thyroidectomy in carriers of RET mutations or following a diagnosis of medullary thyroid carcinoma.

Transfer

Transfer patients for surgical intervention if necessary.

Deterrence/prevention

Start annual 24-hour urine collections for catecholamine concentrations to detect pheochromocytoma at the earliest age possible. Begin annual testing of serum calcium and PTH levels at age 10 years.

Outpatient care

Monitor patients for recurrence of medullary thyroid carcinoma with calcitonin, CEA, and +/- provocative calcitonin testing.

Perform annual screening for hyperparathyroidism with serum calcium and PTH levels in MEN 2A patients. Obtain urinary catecholamine levels on an annual basis to assess for pheochromocytoma. Carefully monitor medication dosage and adverse effects.

Consultations

Consultations with the following specialists may be necessary:

  • Geneticists
  • Endocrinologists
  • Oncologists
Next

Medullary Thyroid Carcinoma Surgery

The advent of genetic analysis has negated the need for pentagastrin stimulation testing to identify patients with hereditary medullary thyroid carcinoma. Carefully screen patients without a family history for pheochromocytoma and hyperparathyroidism because almost 19% of sporadic cases of medullary thyroid carcinoma are index MEN 2A cases.

Calcitonin and CEA determinations remain useful serologic tests to identify recurrent disease. With nearly 100% penetrance of medullary thyroid carcinoma in MEN 2A patients, surgical intervention is recommended in all patients who are identified to carry the MEN2A gene. With genetic analysis available, these patients are often found to have an earlier stage of disease, with many patients having only parafollicular C-cell hyperplasia.

Total thyroidectomy has been recommended for patients as young as 3 years for MEN 2A if they contain the genetic mutation. In patients with the RET genetic mutation for MEN 2B, total thyroidectomy is recommended in infancy because medullary thyroid carcinoma behaves more aggressively in these patients.

In contrast to patients who have sporadic cases of medullary thyroid carcinoma with solitary tumors, patients with MEN 2A have bilateral and multifocal disease.

Surgical strategies

The extent of surgery is controversial. Total thyroidectomy with central neck dissection is recommended for all patients with proven or probable medullary thyroid carcinoma. The need for either a unilateral or a bilateral modified neck dissection is controversial.

The inclusion of a modified neck dissection has been recommended for patients with palpable jugular chain lymphadenopathy. Some surgeons advocate a routine modified neck dissection. Others sample the jugular chain at operation with frozen section, proceeding with dissection only with histologic evidence of metastatic disease.

Children often do not require a node dissection, because their disease is at the hyperplasia stage and has not reached metastatic potential. Moreover, patients undergoing prophylactic thyroidectomy do not require lymphadenectomy.

Patients who have late-stage medullary thyroid cancer with symptomatic or progressive disease who are not surgical candidates may benefit from treatment with vandetanib, a tyrosine-kinase inhibitor that inhibits vascular endothelial growth factor and epidermal growth factor.

Persistent or recurrent calcitonin elevation

The treatment of persistent or recurrent elevations of calcitonin with random testing or following pentagastrin stimulation has been a clinical dilemma. Some investigators have found calcitonin levels to remain stable for approximately 5 years and have recommended surgical excision only for clinically apparent disease. Others have found that 66% of patients with node-positive disease died secondary to medullary thyroid carcinoma and advocate a more aggressive approach to follow-up care and surgery.

Previous
Next

Parathyroid Disease Surgery

Hyperparathyroidism is the least common manifestation of MEN 2A. It usually manifests in patients older than 30 years. Histologically, the parathyroid glands in MEN 2A patients consist of a chief-cell hyperplasia; this hyperplasia is asymmetrical in terms of parathyroid size.

To reduce the risk of postoperative hypocalcemia, remove only grossly abnormal parathyroid glands. If all parathyroid glands are enlarged, a subtotal parathyroidectomy is advocated, leaving an approximately 60mg remnant. Perform a cervical thymectomy because of the increased risk of supernumerary parathyroid glands.[15]

Persistent or recurrent hyperparathyroidism is unusual and less likely to occur in MEN 2A patients than in MEN 1 patients.

Previous
Next

Pheochromocytoma Surgery

Screen all MEN 2A patients for pheochromocytomas. This screening should consist of a 24-hour urine collection for catecholamines and metanephrine. Localization studies are not necessary unless biochemical evidence is consistent with pheochromocytoma.

While all MEN 2A patients may have bilateral adrenal medullary hyperplasia, the tumors may or may not be present bilaterally at the time of initial operation. In this situation, a unilateral adrenalectomy avoids the risk of Addisonian crisis and improves the quality of life by not requiring replacement therapy.

Some investigators have advocated bilateral adrenalectomy in all patients owing to the risk of malignancy (rare) and the operative complications from subsequent surgeries.

The advent of laparoscopic adrenalectomy has substantially decreased the morbidity of adrenalectomy. A subtotal adrenalectomy can be performed to preserve adrenal cortical function, but the risk for recurrence may be increased.

Remember that one fourth of patients with apparently sporadic pheochromocytoma may be carriers of mutations characteristic of syndromes associated with pheochromocytomas.

Previous
Next

Long-Term Monitoring

Patients should be monitored on a lifelong basis for evidence of recurrent disease. After an initial follow-up visit, patients may be evaluated at 6 months, then yearly if they are asymptomatic.

During these evaluations, patients should undergo physical examination, 24-hour urine catecholamine, metanephrine and vanillylmandelic acid, CEA level, calcitonin, and serum calcium testing. If recurrent hypercalcemia is suggested, consider patients for repeat cervical exploration.

If pheochromocytoma is suggested, evaluate patients for surgical resection. This tumor is likely in the remaining contralateral adrenal, although workup should include a CT scan and an MIBG scan to evaluate for recurrence at the resected area or at an extra-adrenal site. Recurrences in the resected area are more common if a subtotal adrenalectomy had been performed initially. The management of calcitonin/CEA elevations has been controversial. Resect any palpable cervical disease.

Some practitioners have advocated routine cervical ultrasonography with exploration for any evidence of recurrence. Many patients remain asymptomatic with elevated calcitonin levels for 20 years or longer.

Previous
 
 
Contributor Information and Disclosures
Author

Melanie L Richards, MD MPHE, Professor, Department of Surgery, Mayo Clinic

Melanie L Richards, MD is a member of the following medical societies: American College of Surgeons, International Association of Endocrine Surgeons, Southwestern Surgical Congress, Western Surgical Association, American Association of Endocrine Surgeons

Disclosure: Nothing to disclose.

Coauthor(s)

Suzanne M Carter, MS Senior Genetic Counselor, Associate, Department of Obstetrics and Gynecology, Division of Reproductive Genetics, Montefiore Medical Center, Albert Einstein College of Medicine

Suzanne M Carter, MS is a member of the following medical societies: American Bar Association

Disclosure: Nothing to disclose.

Susan J Gross, MD, FRCSC, FACOG, FACMG Codirector, Division of Reproduction Genetics, Associate Professor, Department of Obstetrics and Gynecology, Albert Einstein College of Medicine

Susan J Gross, MD, FRCSC, FACOG, FACMG is a member of the following medical societies: American College of Medical Genetics and Genomics, American College of Obstetricians and Gynecologists, American Institute of Ultrasound in Medicine, American Medical Association, American Society of Human Genetics, Royal College of Physicians and Surgeons of Canada

Disclosure: Nothing to disclose.

Chief Editor

George T Griffing, MD Professor Emeritus of Medicine, St Louis University School of Medicine

George T Griffing, MD is a member of the following medical societies: American Association for the Advancement of Science, International Society for Clinical Densitometry, Southern Society for Clinical Investigation, American College of Medical Practice Executives, American Association for Physician Leadership, American College of Physicians, American Diabetes Association, American Federation for Medical Research, American Heart Association, Central Society for Clinical and Translational Research, Endocrine Society

Disclosure: Nothing to disclose.

Acknowledgements

Ruth Freeman, MD, Director of Menopause Research and Treatment Center, Professor, Departments of Medicine and Obstetrics and Gynecology, Montefiore Medical Center, Albert Einstein College of Medicine

Ruth Freeman, MD is a member of the following medical societies: American College of Clinical Endocrinologists

Disclosure: Nothing to disclose.

Romesh Khardori, MD, PhD Professor and Director, Division of Endocrinology, Metabolism, and Molecular Medicine, Southern Illinois University School of Medicine

Romesh Khardori, MD, PhD is a member of the following medical societies: American Association of Clinical Endocrinologists, American College of Physicians, American Diabetes Association, American Federation for Medical Research, American Medical Association, American Society of Andrology, Endocrine Society, and Illinois State Medical Society

Disclosure: Nothing to disclose.

Francisco Talavera, PharmD, PhD Adjunct Assistant Professor, University of Nebraska Medical Center College of Pharmacy; Editor-in-Chief, Medscape Drug Reference

Disclosure: Medscape Reference Salary Employment

References
  1. Calender A. Genetic testing in multiple endocrine neoplasia and related syndromes. Forum (Genova). 1998 Apr-Jun. 8(2):146-59. [Medline].

  2. Verrienti A, Carbone A, Bellitti P, Fabiano MC, De Rose RF, Maranghi M, et al. A NOVEL DOUBLE MUTATION VAL648ILE AND VAL804LEU OF RET PROTO-ONCOGENE IN MULTIPLE ENDOCRINE NEOPLASIA TYPE 2. Endocr Pract. 2015 Aug 6. [Medline].

  3. Zupan A, Glavač D. The development of rapid and accurate screening test for RET hotspot somatic and germline mutations in MEN2 syndromes. Exp Mol Pathol. 2015 Aug 29. [Medline].

  4. Raue F, Frank-Raue K. Genotype-phenotype relationship in multiple endocrine neoplasia type 2. Implications for clinical management. Hormones (Athens). 2009 Jan-Mar. 8(1):23-8. [Medline]. [Full Text].

  5. Moley JF, Skinner M, Gillanders WE, Lairmore TC, Rowland KJ, Traugott AL, et al. Management of the Parathyroid Glands During Preventive Thyroidectomy in Patients With Multiple Endocrine Neoplasia Type 2. Ann Surg. 2015 Oct. 262 (4):641-6. [Medline].

  6. Kluijfhout WP, van Beek DJ, Verrijn Stuart AA, Lodewijk L, Valk GD, van der Zee DC, et al. Postoperative Complications After Prophylactic Thyroidectomy for Very Young Patients With Multiple Endocrine Neoplasia Type 2: Retrospective Cohort Analysis. Medicine (Baltimore). 2015 Jul. 94 (29):e1108. [Medline].

  7. Lallier M, St-Vil D, Giroux M, et al. Prophylactic thyroidectomy for medullary thyroid carcinoma in gene carriers of MEN2 syndrome. J Pediatr Surg. 1998 Jun. 33(6):846-8. [Medline].

  8. van Heurn LW, Schaap C, Sie G, et al. Predictive DNA testing for multiple endocrine neoplasia 2: a therapeutic challenge of prophylactic thyroidectomy in very young children. J Pediatr Surg. 1999 Apr. 34(4):568-71. [Medline].

  9. de Graaf JS, Lips CJ, Rutter JE, van Vroonhoven TJ. Subtotal adrenalectomy for phaeochromocytoma in multiple endocrine neoplasia type 2A. Eur J Surg. 1999 Jun. 165(6):535-8. [Medline].

  10. Edstrom E, Grondal S, Norstrom F, et al. Long term experience after subtotal adrenalectomy for multiple endocrine neoplasia type IIa. Eur J Surg. 1999 May. 165(5):431-5. [Medline].

  11. Gagel RF, Levy ML, Donovan DT, et al. Multiple endocrine neoplasia type 2a associated with cutaneous lichen amyloidosis. Ann Intern Med. 1989 Nov 15. 111(10):802-6. [Medline].

  12. Ilias I, Pacak K. Diagnosis, localization and treatment of pheochromocytoma in MEN 2 syndrome. Endocr Regul. 2009 Apr. 43(2):89-93. [Medline].

  13. Pacak K, Eisenhofer G, Ilias I. Diagnosis of pheochromocytoma with special emphasis on MEN2 syndrome. Hormones (Athens). 2009 Apr-Jun. 8(2):111-6. [Medline]. [Full Text].

  14. Taïeb D, Sebag F, Barlier A, et al. 18F-FDG avidity of pheochromocytomas and paragangliomas: a new molecular imaging signature?. J Nucl Med. 2009 May. 50(5):711-7. [Medline].

  15. Yoshida S, Imai T, Kikumori T, et al. Long term parathyroid function following total parathyroidectomy with autotransplantation in adult patients with MEN2A. Endocr J. 2009 Aug. 56(4):545-51. [Medline].

  16. Calmettes C, Ponder BA, Fischer JA, Raue F. Early diagnosis of the multiple endocrine neoplasia type 2 syndrome: consensus statement. European Community Concerted Action: Medullary Thyroid Carcinoma. Eur J Clin Invest. 1992 Nov. 22(11):755-60. [Medline].

  17. Carling T. Multiple endocrine neoplasia syndrome: genetic basis for clinical management. Curr Opin Oncol. 2005 Jan. 17(1):7-12. [Medline].

  18. Chi DD, Moley JF. Medullary thyroid carcinoma: genetic advances, treatment recommendations, and the approach to the patient with persistent hypercalcitoninemia. Surg Oncol Clin N Am. 1998 Oct. 7(4):681-706. [Medline].

  19. Evans DB, Fleming JB, Lee JE, et al. The surgical treatment of medullary thyroid carcinoma. Semin Surg Oncol. 1999 Jan-Feb. 16(1):50-63. [Medline].

  20. Frank-Raue K, Rondot S, Hoeppner W, Goretzki P, Raue F, Meng W. Coincidence of multiple endocrine neoplasia types 1 and 2: mutations in the RET protooncogene and MEN1 tumor suppressor gene in a family presenting with recurrent primary hyperparathyroidism. J Clin Endocrinol Metab. 2005 Jul. 90(7):4063-7. [Medline].

  21. Gagel RF, Tashjian AH Jr, Cummings T, et al. The clinical outcome of prospective screening for multiple endocrine neoplasia type 2a. An 18-year experience. N Engl J Med. 1988 Feb 25. 318(8):478-84. [Medline].

  22. Goretzki PE, Hoppner W, Dotzenrath C, et al. Genetic and biochemical screening for endocrine disease. World J Surg. 1998 Dec. 22(12):1202-7. [Medline].

  23. Iler MA, King DR, Ginn-Pease ME, et al. Multiple endocrine neoplasia type 2A: a 25-year review. J Pediatr Surg. 1999 Jan. 34(1):92-6; discussion 96-7. [Medline].

  24. Johnston LB, Chew SL, Trainer PJ, et al. Screening children at risk of developing inherited endocrine neoplasia syndromes. Clin Endocrinol (Oxf). 2000 Feb. 52(2):127-36. [Medline].

  25. Koch CA. Molecular pathogenesis of MEN2-associated tumors. Fam Cancer. 2005. 4(1):3-7. [Medline].

  26. Lips CJ. Clinical management of the multiple endocrine neoplasia syndromes: results of a computerized opinion poll at the Sixth International Workshop on Multiple Endocrine Neoplasia and von Hippel-Lindau disease. J Intern Med. 1998 Jun. 243(6):589-94. [Medline].

  27. Moore SW, Appfelstaedt J, Zaahl MG. Familial medullary carcinoma prevention, risk evaluation, and RET in children of families with MEN2. J Pediatr Surg. Feb. 42:326-32. [Medline].

  28. Neumann HP, Bausch B, McWhinney SR. Germ-line mutations in nonsyndromic pheochromocytoma. N Engl J Med. 2002 May 9. 346(19):1459-66. [Medline].

  29. Romeo G, Ceccherini I, Celli J, et al. Association of multiple endocrine neoplasia type 2 and Hirschsprung disease. J Intern Med. 1998 Jun. 243(6):515-20. [Medline].

  30. Wick MJ. Clinical and molecular aspects of multiple endocrine neoplasia. Clin Lab Med. 1997 Mar. 17(1):39-57. [Medline].

 
Previous
Next
 
 
 
 
All material on this website is protected by copyright, Copyright © 1994-2016 by WebMD LLC. This website also contains material copyrighted by 3rd parties.